(Q37534547)

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

review article

1 reference

title

Autologous and allogeneic stem cell transplantation: rising therapeutic promise for mantle cell lymphoma (English)

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

stem cell transplantation

1 February 2020

main subject

1 reference

1

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

2

Issa F Khouri

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

publication date

1 August 2009

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

volume

50

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

issue

8

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

page(s)

1239-1248

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

Improvement of Overall Survival in Advanced Stage Mantle Cell Lymphoma

1 February 2020

cites work

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

High-dose chemoradiotherapy and anti-B-cell monoclonal antibody-purged autologous bone marrow transplantation in mantle-cell lymphoma: no evidence for long-term remission

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Sequential chemotherapy by CHOP and DHAP regimens followed by high-dose therapy with stem cell transplantation induces a high rate of complete response and improves event-free survival in mantle cell lymphoma: a prospective study.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Early consolidation by myeloablative radiochemotherapy followed by autologous stem cell transplantation in first remission significantly prolongs progression-free survival in mantle-cell lymphoma: results of a prospective randomized trial of the Eur

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Immunochemotherapy with rituximab and cyclophosphamide, doxorubicin, vincristine, and prednisone significantly improves response and time to treatment failure, but not long-term outcome in patients with previously untreated mantle cell lymphoma: res

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

High rate of durable remissions after treatment of newly diagnosed aggressive mantle-cell lymphoma with rituximab plus hyper-CVAD alternating with rituximab plus high-dose methotrexate and cytarabine

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

High-dose therapy improves progression-free survival and survival in relapsed follicular non-Hodgkin's lymphoma: results from the randomized European CUP trial

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

High-dose chemotherapy with hematopoietic stem-cell rescue for multiple myeloma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Outcome of autologous transplantation for mantle cell lymphoma: a study by the European Blood and Bone Marrow Transplant and Autologous Blood and Marrow Transplant Registries

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Mature results of the M. D. Anderson Cancer Center risk-adapted transplantation strategy in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Primary treatment with autologous stem cell transplantation in mantle cell lymphoma: outcome related to remission pretransplant

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Outcomes of autologous and allogeneic blood or marrow transplantation for mantle cell lymphoma.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Long-term remission in mantle cell lymphoma following high-dose sequential chemotherapy and in vivo rituximab-purged stem cell autografting (R-HDS regimen).

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Chemotherapy with rituximab followed by high-dose therapy and autologous stem cell transplantation in patients with mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Rituximab-augmented myeloablation for first-line autologous stem cell transplantation for mantle cell lymphoma: effects on molecular response and clinical outcome.

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Long-term progression-free survival of mantle cell lymphoma after intensive front-line immunochemotherapy with in vivo-purged stem cell rescue: a nonrandomized phase 2 multicenter study by the Nordic Lymphoma Group

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Nonmyeloablative stem cell transplantation in follicular B-cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Nonablative allogeneic stem cell transplantation for chronic lymphocytic leukemia: impact of rituximab on immunomodulation and survival

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Nonmyeloablative allogeneic hematopoietic transplantation: a promising salvage therapy for patients with non-Hodgkin's lymphoma whose disease has failed a prior autologous transplantation

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Allogeneic hematopoietic cell transplantation after fludarabine and 2 Gy total body irradiation for relapsed and refractory mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Relapse risk in patients with malignant diseases given allogeneic hematopoietic cell transplantation after nonmyeloablative conditioning

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Results of alemtuzumab-based reduced-intensity allogeneic transplantation for chronic lymphocytic leukemia: a British Society of Blood and Marrow Transplantation Study

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Outcomes after alemtuzumab-containing reduced-intensity allogeneic transplantation regimen for relapsed and refractory non-Hodgkin lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Nonmyeloablative transplantation with or without alemtuzumab: comparison between 2 prospective studies in patients with lymphoproliferative disorders

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

A new prognostic index (MIPI) for patients with advanced-stage mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Phase II clinical experience with the novel proteasome inhibitor bortezomib in patients with indolent non-Hodgkin's lymphoma and mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

Monoclonal Antibody Therapy for B-Cell Non-Hodgkin's Lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

The proliferation gene expression signature is a quantitative integrator of oncogenic events that predicts survival in mantle cell lymphoma

21 January 2018

1 reference

https://api.crossref.org/works/10.1080%2F10428190903026518

10.1080/10428190903026518

21 January 2018

Identifiers

DOI

1 reference

https://www.ebi.ac.uk/europepmc/webservices/rest/search?query=EXT_ID:19562639%20AND%20SRC:MED&resulttype=core&format=json

1 February 2020

1 reference